Catalyst Brief

← Calendar

Readoutin 14d

Boehringer Ingelheim — BI 690517

Phase 3 primary completion: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin).

Date
Dec 2026
Type
Readout
Indication
Kidney Disease, Chronic

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Boehringer Ingelheim

  1. Apr2027